CH

Chungen Pan


Patents



  1. Pan, C., Duncan, R. Recombinant oncolytic viruses for treatment of metastatic cancers.
    Canadian Patent 2,971,832. Filed June 23, 2017.
  2. Jiang, S., Pan, C. Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors.
    US 7,919,101. Filed August 13, 2008. Issued April 5, 2011. Published as: CA2734081A1, EP2321342A2, EP2377880A2, EP2377880A3, US20100040631, WO2010019717A2, WO2010019717A3.
  3. Jiang, S., Pan, c. Bifunctional molecules for inhibiting HIV entry.
    US 8,828,931. Filed May 3, 2008. Issued September 9, 2014; US Application No. 12/474,105. Published as: CA2724900A1, EP2291392A1, EP2291392B1, US20090298774, WO2009155064A1.
  4. Jiang, S., Pan, C., Lu, L. Bifunctional molecules for inactivating HIV and blocking HIV entry.
    US 8,828,932. Filed May 3, 2010. Issued September 9, 2014, US Application No. 13/100,031; EP2566493 (Filed March 5, 2011. Issued May 2, 2015). Published as: CA2794632A1, CN102883740A, CN102883740B, EP2566493A1, EP2566493B1, US20110269676, WO2011140092A1. Chinese patent: 201180022594.0 (Filed 2011-5-3, PCT enter into China    ：2012-11-5).
  5. Jiang, S., Qi, Z., Pan, C. Immunoenhancer-linked oligomeric HIV envelope peptides.
    US 8,936,789. Filed October 16, 2009; US Appl. No.: 61/106,101, filed on Oct. 16, 2008. Issued January 20, 2015. Published as: CA2739288A1, EP2334329A1, US20100098724, WO2010045613A1.
  6. Jiang, S., Qi, Z., Chen, X., Pan, C. Stabilized trimeric HIV-1 gp41 fusion inhibitor polypeptide comprising the N-terminal heptad repeat (NHR) and folden (Fd) trimerization motif.
    US 9,115,186. Filed February 8, 2010. Issued August 25, 2015; US Appl. No.: 61/151,110. Continuation patent application (Trimeric HIV fusion inhibitors for treating or preventing HIV infection): 14/796,725, filed on 7-10-2015. Published as: CN102307588A, EP2393507A2, US9115186, US20100204120, US20150306174, WO2010091373A2, WO2010091373A3, WO2010091373A8.

Selected Publications



  1. Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, Liu S, Pan C. (2020). Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.
    Microbes Infect. Epub 2020 May 13. 
  2.  Gao T, Pan X, Pan C. (2020). The fate of house cats during the COVID-19 pandemic.
    Microbes Infect. Epub 2020 April 22. 

  3.  Yu F, Du L, Ojcius DM, Pan C, Jiang S. (2020). Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China.
    Microbes Infect. 22(2):74-79. Epub 2020 Feb 1. 
  4.  Pan X, Ojcius DM, Gao T, Li Z, Pan C, Pan C. (2020). Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases.
    Microbes Infect. 22(2):86-91. Epub 2020 Feb 20. 
  5.  Le Boeuf, F., Gebremeskel, S., McMullen, N., Greenshields, A., Bell, J., Johnston, B., Pan, C and Duncan R. (2017). Reovirus FAST protein enhances Vesicular Stomatitis Virus oncolytic virotherapy in primary and metastatic tumor models. Molecular Therapy - Oncolytics. 6:80-89. 
  6. Wei, M., Chen, Y., Wang, Y., Xu, J., Xiong, W., Jiang, S. and Pan, C. (2014). An influenza A virus vaccine candidate containing the conserved sequence in HA2 of H5N1 induces broadly cross-reactive antibody responses to HA of H5N1, H1N1, and H3N2 subtypes. J. Sun Yat-Sen Univ. (Med. Sci.). 35(3):321-328.  
  7. Lu, L., Wei, M., Chen, Y., Xiong, W.,Yu, F.,  Qi, Z., Jiang, S. and Pan, C. (2013). F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. Microbes Infect. 15(13):887-94. 
  8.  Wang, X., Zhou, S., Chen, Y., Wei, M., Xiong, W., Yi, X., Jiang, S. and Pan, C. (2013). Multiple amino acid mutations in viral RNA polymerase may synergistically enhance the transmissibility and/or virulence of the 2009 pandemic influenza (H1N1) virus. Acta Virol. 57(1): 35-40.
  9.  Lu, L., Pan, C., Li, Y., Lu, H., He, W. and Jiang, S. (2012). A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
    Retrovirology. 9:104 
  10. Wang, X., Xiong, W., Ma, X., Wei M., Chen, Y., Lu, L., Debnath, AK, Jiang, S. and Pan, C. (2012).
    The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for vial fusion and entry.
    PLoS One. 7(9): e44874    .
  11. Ma, X., Zhou, S., Wei, M., Li, J., Chen, Y., Wang, X., Jiang, S. and Pan, C. (2012).
    Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus - xenotropic murine leukemia virus-related virus (XMRV).
    Virus Genes. 45(2):218-224.
  12. Pan, C., Ma, X. and Jiang, S. (2012). What can academia learn from XMRV studies?
    Nature Rev. Urol. 9(3):174.
  13. Cai, L., Pan, C., Xu, L., Shui, Y., Liu, K. and Jiang, S. (2012).Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
    TheFASEB J.26(3):1018-26.     
  14. Pan, C., Cai, L., Lu, H., Lu, L., Jiang, S. (2011). A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 with high potency and stability.
    J. Biol. Chem. 286     (32):28425-34. 
  15. Qi Z, Pan C., Lu H, Shui Y, Li L, Li X, Xu X, Liu S, Jiang S. (2010). A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
    Biochem. Biophys Res. Commun.
    398, 506-512. 
  16. Pan, C., Liu, S., and Jiang, S. (2010). HIV-1 gp41 fusion intermediate: a target for HIV therapeutics (invited review). J. Formos. Med. Assoc. 109 (2): 94-105. 
  17. Pan C., Cheung B, Tan S, Li C, Li L, Liu S, Jiang S. (2010). Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS One. 5(3):e9549.
  18. Jin L, Pan C., Qi Z, Zhou ZH, Jiang S.
    (2010). Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41.
    Acta Crystallogr Sect F Struct Biol Cryst Commun.
    66(Pt 7):854-7. 
  19. Pan, C. , Cai, L., Lu, H., Qi, Z., Jiang, S. (2009).Combinations of first and next generation HIV fusion inhibitors exhibits highly potent synergism against
    Enfuvirtide-sensitive and resistant HIV-1 strains.
    J. Virol. 83, 7862-7872. 
  20. Pan, C. , Lu, H., Qi, Z., Jiang, S. (2009).Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    AIDS. 23, 639-641. 
  21. Pan, C., Wang, G., Liao, M., Zhang, G.H., Jiang, S. (2009). High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission. Biochem. Biophys. Res. Commun.  385, 402-407. 
  22. Pan, C., Jiang, S. (2009). E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans.
    PLoS Currents: Influenza. Sept 29:RRN1044. 




No items yet!

Your experience on this site will be improved by allowing cookies.